abstract |
The present invention relates to a pharmaceutical composition comprising a HMG-CoA reductase inhibitor, in particular a statin and acetylsalicylic acid, in a manner that minimizes the interaction of acetylsalicylic acid with statins, for the prevention or treatment of cardiovascular disease disease. |